Tyra Biosciences, Inc.
TYRAHealthcareNASDAQBiotechnology · Last scanned Oct 21, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 20
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The $1.41B market capitalization puts TYRA squarely in small-cap range for its industry. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Market Cap
$1.41B
Beta
0.75
P/E (TTM)
—
P/E (Fwd)
-7.39
EPS (TTM)
$-2.53
EPS (Fwd)
$-2.77
ROE
-45.3%
ROA
-28.5%
Cash
$353.9M
Total Debt
$5.6M
Free CF
-$63.1M
52W Change
39.2%
Annual Financials
Cash vs Debt
Where TYRA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, TYRA finished 35.19% below its 150-day moving average ($29.84) and 35.98% below its 200-day moving average ($30.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TYRA overbought or oversold?
At the October 20, 2026 close, TYRA's RSI(14) was 29.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $353.9M in cash and $5.6M in debt, TYRA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$63.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -45.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, TYRA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TYRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.